Jonathan M. DeLiberty

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Nicole M. Baker, E. Petricoin, D. Esposito, 2019, Cancer discovery.

Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors.

E. Petricoin, K. Wennerberg, C. Der, 2021, Cancer research.

Functional and biological heterogeneity of KRASQ61 mutations

E. Petricoin, C. Der, N. Rashid, 2022, Science Signaling.

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

E. Petricoin, C. Der, C. Kuo, 2021, Cell reports.

Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain.

Kirsten L. Bryant, R. Robb, Claire E Gates, 2022, Advances in cancer research.

Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

Jian Yu, D. Stolz, R. Ferris, 2021, Oncogene.